Eric Tran
Eric Tran has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Bayldon Baell
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
3 shared publications - Amandeep Kaur
Medicinal Chemistry Monash Institute of Pharmaceutical Sciences Monash University Melbourne VIC Australia
2 shared publications - Manuela Jörg
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
2 shared publications - Yi Sing Gee
Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
2 shared publications Andrew Xi-Yuan Tang
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences
1 shared publication- Chen-Yi Cheung
Department of Microbiology and Immunology, Otago School of Medical Sciences University of Otago Dunedin 9054 New Zealand
1 shared publication
Latest Publications
- 4 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (9) , 6746-6754
Nitroreductase-Activated Probes for Monitoring Hypoxia
Hypoxia, a hallmark of solid tumors, complicates cancer treatment by reducing the efficacy of radiotherapy and chemotherapy. To optimize strategies for hypoxia detection and targeted cancer therapy, this work explores the development of hypoxia-responsive fluorescent probes. In this study, we compared various nitroaromatic groups and both elimination-based and cyclization-based self-immolative designs to study nitroreductase (NTR) activation. The research highlighted differences in activation response among the probes, with elimination-based probes (8b-8d) showing faster activation compared to cyclization-based probes (8f-8i). Furthermore, analogs with different nitroaromatic linkers exhibited different selectivity profiles for common biomolecules and ions. These subtle differences were also apparent in our cellular hypoxia assays, underscoring the importance of carefully selecting the nitroaromatic moiety and probe/drug design for applications such as diagnostic tools to detect hypoxia or targeted cancer therapies.
- 4 September 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (9) , 6746-6754
Nitroreductase-Activated Probes for Monitoring Hypoxia
Hypoxia, a hallmark of solid tumors, complicates cancer treatment by reducing the efficacy of radiotherapy and chemotherapy. To optimize strategies for hypoxia detection and targeted cancer therapy, this work explores the development of hypoxia-responsive fluorescent probes. In this study, we compared various nitroaromatic groups and both elimination-based and cyclization-based self-immolative designs to study nitroreductase (NTR) activation. The research highlighted differences in activation response among the probes, with elimination-based probes (8b-8d) showing faster activation compared to cyclization-based probes (8f-8i). Furthermore, analogs with different nitroaromatic linkers exhibited different selectivity profiles for common biomolecules and ions. These subtle differences were also apparent in our cellular hypoxia assays, underscoring the importance of carefully selecting the nitroaromatic moiety and probe/drug design for applications such as diagnostic tools to detect hypoxia or targeted cancer therapies.
- Open Access
- 25 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400482
Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F420 biosynthesis (fbiC), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.
- 25 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (24) , e202400482
Open AccessPhenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug‐resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran‐resorufin conjugate 1 was identified as a potent sub‐micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F420 biosynthesis (fbiC), suggesting that 1 undergoes prodrug activation in a manner similar to anti‐tuberculosis prodrug pretomanid. Exploration of the structure‐activity relationship led to the discovery of novel resorufin analogues that do not rely on the deazaflavin‐dependent nitroreductase (Ddn) bioactivation pathway for their antimycobacterial activity. These analogues are of interest as they work through an alternative, currently unknown mechanism that may expand our chemical arsenal towards the treatment of this devastating disease.
- Open Access
- 27 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-27
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors can be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to α-PD-1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.
- 27 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-27
Open AccessA small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors can be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to α-PD-1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.